The remarkable success of cancer immunotherapies has provided new hope to cancer
patients. Unfortunately, a significant proportion of patients remain unable to respond to …

Purpose of Review Adolescents and young adults (AYAs) with cancer are a vulnerable
population with unique needs that are under-recognized and often overlooked by healthcare …

Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved
for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse …

The reactogenicity profile of the Pfizer-BioNTech COVID-19 vaccine approved by the US
Food and Drug Administration has demonstrated generally transient, mild-to-moderate local …

Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in cancer
immunotherapy; however, it can be associated with life-threatening neurotoxicity linked to blood-…

Cutaneous T-cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical
courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an …

The impact of physical activity (PA) on lymphoma survival is not known. The association of
PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) …

Patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL) after
anti-CD19 chimeric antigen receptor T-cell therapy (CART19) have poor prognosis with a …

Background Advances in understanding of cancer biology, genomics, epigenomics, and
immunology have resulted in development of several therapeutic options that expand cancer …

Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase
inhibitors (BTKi) with inhibitors of mammalian target of rapamycin (mTOR) and …